Vaxinano is a french biotechnology company, developing a new generation of  vaccines that are more efficient and faster to deploy to prevent or treat infectious diseases. 

The vaccine platform is based on Stellar-NP technology that confer highly stable, adjuvant-free vaccine for an effective and long-lasting response to protect against the most difficult pathogens, such as parasites, viruses, bacteria or fungi.

Vaxinano

Office 84 focuses on R&D in vaccines and immunology, supporting project leadership and consultancy in healthcare innovation.

People (4)

Jobs (0)

Other offices